TriangleNT-I7 for multiple myeloma (NCT07200089)
NT-I7 for multiple myeloma trial for Multiple Myeloma (NCT07200089). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for multiple myeloma that has returned or not responded, in patients receiving the BCMA CAR T therapy ciltacabtagene autoleucel.
CAR T responses can be strong but are often not durable. The idea: help the cells last. NT-I7, a long-acting form of interleukin-7, a protein that supports T cell growth, is given by injection on days 14 and 35 after the infusion.
The study has two stages. First, dose finding. Later, the expansion is randomized and double blind: some patients receive NT-I7 and others receive a placebo. At Washington University in St. Louis, Michael Slade leads this early safety study.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.